Palvella Therapeutics (PVLA) Receivables - Other (2019 - 2024)

Palvella Therapeutics (PVLA) has 4 years of Receivables - Other data on file, last reported at $3.0 million in Q2 2024.

• Receivables - Other for Q2 2024 came in at $3.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $3.0 million (changed N/A YoY), and the FY2023 annual result was $2.3 million, down 51.25% from the prior year.
• Receivables - Other eased to $3.0 million in Q2 2024 per PVLA's latest filing, from $3.1 million in the prior quarter.
• Over five years, Receivables - Other peaked at $4.8 million in Q4 2022 and troughed at $2.3 million in Q4 2023.
• A 3-year average of $3.3 million and a median of $3.1 million in 2024 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 51.25% in 2023 and fell as far as 51.25% in 2023.
• A 3-year view of Receivables - Other shows it stood at $4.8 million in 2022, then slumped by 51.25% to $2.3 million in 2023, then surged by 31.08% to $3.0 million in 2024.
• Business Quant data shows PVLA's Receivables - Other at $3.0 million in Q2 2024, $3.1 million in Q1 2024, and $2.3 million in Q4 2023.